RxDoctor Payments Data

Jane Clark

Psychiatric/Mental Health · Hartford, CTNPI 1639262579

Payments from drug & device makers

$2,915in general payments, 2019–2025

Across 123 payments — averaging $23.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Otsuka America Pharmaceutical, Inc.$540
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$386
  • Johnson & Johnson$168
  • Sunovion Pharmaceuticals Inc.$100
  • Axsome Therapeutics, Inc.$68
  • plus $145 from 4 others

What the payments were for

  • Food & beverage$2,86698%
  • Education$492%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,915 in reported general payments places this provider in the 85th percentile of 679 psychiatric/mental health providers in Connecticut.

See all psychiatric/mental health providers in Connecticut

Medicare billing

Part B allowed, 2024
$26,474
Medicare patients
23
Services billed
313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl15$32,663
Lurasidone Hcl44$12,689
TrintellixVortioxetine Hydrobromide12$11,597
Divalproex Sodium ErDivalproex Sodium12$3,847
Desvenlafaxine Succinate ErDesvenlafaxine Succinate20$1,904
Bupropion XlBupropion Hcl45$1,201
Mirtazapine26$1,004
Paroxetine ErParoxetine Hcl11$941
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine26$864
Venlafaxine Hcl ErVenlafaxine Hcl22$713
Clonazepam78$671
Quetiapine Fumarate12$648
Sertraline Hcl37$580
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine23$495
Duloxetine Hcl19$429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,509$32,66315 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$22$11,59712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 679 psychiatric/mental health providers in Connecticut.

Other psychiatric/mental health in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →